Shanghai MicroPort MedBot (Group) Co., Ltd. (Stock Code: 2252) convened its 2025 extraordinary general meeting (EGM) on 25 November 2025. Shareholders holding 599,487,480 voting shares, representing approximately 58.1% of the total issued shares, participated. All six ordinary resolutions and one special resolution were approved by poll.

Among the key outcomes, six new Directors were appointed at the conclusion of the EGM: four non-executive Directors (Dr. Zhaohua Chang, who also assumes the role of chairperson of the board effective 25 November 2025, along with Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, and Ms. Min Liang) and two independent non-executive Directors (Dr. Guoen Liu and Mr. Jonathan H. Chou). Further, the Company’s Articles of Association and the Rules of Procedure for the General Meeting of Shareholders were amended following approval of a special resolution.

Changes have also been introduced to certain board committees. The audit committee now comprises independent non-executive Directors Mr. Chou and Mr. Wai Man Chung, alongside non-executive Director Mr. Ashida, with Mr. Chou appointed as chairperson. The remuneration and appraisal committee consists of Dr. Liu, Mr. Chou, and Mr. Ashida, chaired by Dr. Liu. The nomination committee includes Mr. Haisong Yao, Mr. Chung, and Ms. Liang, with Mr. Yao acting as chairperson. The strategy and development committee comprises Dr. Liu, Mr. Shirafuji, and executive Director Dr. Chao He, chaired by Dr. Liu. Meanwhile, the commercialisation committee includes Mr. Shirafuji, Mr. Chen Chen, executive Director Mr. Yu Liu, and Ms. Liang, with Mr. Shirafuji serving as chairperson.

In addition, there is a change in authorised representative: Dr. Chang replaces Mr. Hongbin Sun as the authorised representative for the purpose of Rule 3.05 of the Listing Rules, effective 25 November 2025.